0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

METHOCARBAMOL-NEW AGENT IN TREATMENT OF NEUROLOGICAL AND NEUROMUSCULAR DISEASES

Desmond S. O'Doherty, M.D.; Charles D. Shields, M.D.
JAMA. 1958;167(2):160-163. doi:10.1001/jama.1958.02990190014003.
Text Size: A A A
Published online

If one accepts the theory that spasticity is the result of the release of the spinal cord from the inhibition of higher centers, in both the brain stem and cortex, resulting in a sustained reflex increase in tonus, extensor in the lower and flexor in the upper extremities, then it will be seen that a drug, to be effective, must either restore the "inhibition" to the cord or break up the sustained reflex activity. The ideal lissive agent should have a long therapeutic effect, be available in an oral preparation, and, if side-effects are present, have a ratio between toxic and therapeutic dosage great enough that the side-effects are not more incapacitating than the primary condition. With methocarbamol a good result was obtained in 72% of patients with both acute and chronic spasm. An improvement in all patients with incoordination was observed. Methocarbamol is of value in muscle spasm and severe flexor spasms accompanying cord disease and has as well a more limited use in the treatment of incoordination.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();